Earnings Call Intelligence Subscribe
Home › Call Sheets › ABT › Q1'26
Call sheet · Q1'26

Abbott Laboratories (ABT)

Q1'26 earnings call · held April 16, 2026 · compared with the Q4'25 call · management-credibility review
9/12
Disclosure score
3 medium, 3 low flags
Financial quality
Bottom line
The real story is Core Lab Diagnostics quietly turning the corner with sequential growth and China headwinds mostly behind them - this $5B+ business inflecting higher is the sleeper catalyst nobody's talking about. Yes, CGM growth slowed to 7.5% but Ford's 45-minute defensive ramble about market penetration screams worry about prescription trend weakness that's not just 'tender delays.' The binding constraint is Nutrition's volume recovery timeline - they need six months to transition back to sustainable growth, and early pricing action results will determine if this is quarters or years of pain. Ford's most revealing quote: 'I'm not going to try and call what type of flu season we're going to have' - basically admitting their respiratory forecasting is broken. My view changes if Core Lab sequential growth accelerates above 5% in Q2 or if CGM returns to double-digits as promised.

The 30-second version

  • Core Lab Diagnostics quietly inflecting - sequential AND year-over-year growth
  • Exact Sciences integration masks organic deceleration in base business
  • CGM growth narrative cracking - prescription trends weak, tender delays, shelf restocking laps

What changed this quarter

MetricQ4'25Q1'26Change
Revenue Growth (Comparable)3.8% organic Q43.7% comparable Q1Essentially flat growth with Exact in the mix
Adjusted EPS$1.50 (+12% YoY) Q4$1.15 (+6% YoY) Q1Growth rate cut in half
CGM Revenue12% growth Q47.5% growth Q1450 bps deceleration
Core Lab Diagnostics3.5% growth Q43% growth Q1Modest decel but sequential growth noted
ElectrophysiologyDouble-digit Q413% growth Q1Sustained momentum with PFA launches
Nutrition SalesDeclined Q4Slightly ahead expectations Q1Still negative but pricing actions showing early signs
Cancer Diagnostics (Comparable)N/A13% growth Q1New disclosure from Exact integration
Respiratory/Molecular DiagnosticsN/A specific-10% decline Q1Weaker than expected respiratory season
EPD Growth7% Q49% Q1200 bps acceleration
Medical Devices10.5% Q48.5% Q1200 bps deceleration

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full ABT Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.